NCT03330197 - A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

September 10, 2021

Study Completion Date

September 10, 2021

Conditions

Pediatric Brain TumorDiffuse Intrinsic Pontine Glioma

Interventions

BIOLOGICAL

Ad-RTS-hIL-12

2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12

DRUG

Oral Veledimex - Arm 1 (Pediatric Brain Tumor)

1 dose level (10mg/day) 15 oral daily doses of veledimex

DRUG

Oral Veledimex - Arm 2 (DIPG)

2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex

Trial Locations (3)

Lurie Children's Hospital of Chicago, Chicago

University of California San Francisco, Benioff Children's Hospital, San Francisco

Dana- Farber Cancer Institute, Boston